Daniel Mrak - Concepedia

Author

Daniel Mrak

Medical University of Vienna ORCID

Also Known As

D Mrak, D. Mrak, Daniel Mrak

Publications

814

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Klinik Hietzing Hanusch Hospital Sigmund Freud Privatuniversität Wien

About

Daniel Mrak is an author at Medical University of Vienna specializing in vaccine development, medicine, and vaccine safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	48
2	Immunology	2	2	48
3	Epidemiology	1	1	33
4	Immunotherapy	1	1	33
5	Precision Vaccinology	1	1	15

Daniel Mrak

Publications

633

Citations

H-Index

Page 1

	Year	Citations
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Annals of the Rheumatic Diseases	2021	244
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial Michael Bonelli, Helga Radner, Andreas Kerschbaumer, Annals of the Rheumatic Diseases	2022	92
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial Michael Bonelli, Daniel Mrak, Selma Tobudic, Annals of the Rheumatic Diseases	2022	60
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls Felix Kartnig, Daniel Mrak, Elisabeth Simader, Annals of the Rheumatic Diseases	2022	42
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Nature Communications Vector Vaccine GroupCovid-19 Booster VaccinationImmunologyImmunotherapyCovid-19	2022	33
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study Daniel Mrak, Elisabeth Simader, Daniela Sieghart, Annals of the Rheumatic Diseases	2022	32
Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases Daniel Mrak, Felix Kartnig, Daniela Sieghart, Journal of Autoimmunity	2022	25
Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis Elisabeth Simader, Selma Tobudic, Péter Mandl, Annals of the Rheumatic Diseases	2021	22
Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study Péter Mandl, Selma Tobudic, H. Haslacher, Annals of the Rheumatic Diseases	2022	19
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial Michael Bonelli, Daniel Mrak, Selma Tobudic, Additional Booster VaccinationImmunologyImmunosuppressed PatientsPrimary Mrna VaccinationSars-cov-2 Antibody Seroconversion	2021	15

Page 1